BioXcel Therapeutics, Inc.
BTAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 64.2% | 268% | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 5.4% | 8.7% | 94.7% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,948.9% | -11,987% | -41,924.5% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,630.1% | -12,974.9% | -44,201.9% | – |
| EPS Diluted | -23.51 | -98.35 | -94.67 | -64.87 |
| % Growth | 76.1% | -3.9% | -45.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |